A reciprocal role of prostate cancer on stromal DNA damage

Oncogene

Volumn 33, Issue 41, 2013, Pages 4924-4931

  Banerjee, J ^a,e,f   Mishra, R ^b,e   Li, X ^a,f   Ii, R S Jackson ^a,c   Sharma, A ^d   Bhowmick, N A ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d University of Tennessee   (United States)

^e UNIVERSITY OF TENNESSEE   (United States)

^f VAN ANDEL INSTITUTE   (United States)

Author keywords

DNA methylation; IL 6; Prostate cancer; Stromal coevolution; TGF beta

Indexed keywords

CYCLOHEXIMIDE; DNA METHYLTRANSFERASE 1; GLUTATHIONE TRANSFERASE P1; HISTONE H3; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; DNA (CYTOSINE 5) METHYLTRANSFERASE; HISTONE; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DNA METHYLATION; FIBROBLAST; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LNCAP CELL LINE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DNA REPAIR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SCID MOUSE; STROMA CELL;

ANIMALS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; EPIGENESIS, GENETIC; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE S-TRANSFERASE PI; HISTONES; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; OXIDATIVE STRESS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84921787443     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.431     Document Type: Article

References (40)

1. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-851.
2. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-337.
3. Nguyen DX, Bos PD, Massague J. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
4. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8: 2912-2923.
5. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinomaassociated fibroblasts direct tumor progression of initiate d human prostatic epithelium. Cancer Res 1999; 59: 5002-5011.
6. Cunha GR. Androgenic effects upon prostatic epithelium are mediated via trophic influences from stroma. Prog Clin Biol Res 1984; 145: 81-102.
7. Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG et al. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res 2008; 68: 4709-4718.
8. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008; 40: 650-655.
9. Campbell I, Polyak K, Haviv I. Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. Cancer Res 2009; 69: 6765-6768.
10. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001; 93: 1747-1752.
11. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
12. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J et al. Senescenceassociated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853-2868.
13. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004; 64: 3215-3222.
14. Placencio VR, Li X, Sherrill TP, Fritz G, Bhowmick NA. Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS One 2010; 5: e12920.
15. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7: 192-201.
16. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13: 616-630.
17. Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000; 11: 159-168.
18. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T et al. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 2008; 27: 7118-7130.
19. Jackson 2nd RS, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J et al. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. NeoplAsia 2012; 14: 656-665.
20. Hodge DR, Cho E, Copeland TD, Guszczynski T, Yang E, Seth AK et al. IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase. Cancer genomics proteomics 2007; 4: 387-398.
21. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-376.
22. Du Z, Song J, Wang Y, Zhao Y, Guda K, Yang S et al. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci Signal 2010; 3: 80.
23. Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D et al. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res 2009; 15: 3979-3989.
24. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012; 18: 1359-1368.
25. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999; 9: M57-M60.
26. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 49-56.
27. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166: 2472-2483.
28. Maruyama R, Choudhury S, Kowalczyk A, Bessarabova M, Beresford-Smith B, Conway T et al. Epigenetic regulation of cell type-specific expression patterns in the human mammary epithelium. PLoS Genet 2011; 7: e1001369.
29. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proc Natl Acad Sci USA 2001; 98: 12072-12077.
30. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 2008; 105: 14867-14872.
31. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007; 109: 1705-1714.
32. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
33. Shen H, Laird PW. In epigenetic therapy, less is more. Cell Stem Cell 2012; 10: 353-354.
34. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, Rojas A et al. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology 2009; 136: 1680-1688.
35. Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000; 26: 16-17.
36. Martinez-Ferrer M, Afshar-Sherif AR, Uwamariya C, de Crombrugghe B, Davidson JM, Bhowmick NA. Dermal transforming growth factor-beta responsiveness mediates wound contraction and epithelial closure. Am J Pathol 2010; 176: 98-107.
37. Li X, Martinez-Ferrer M, Botta V, Uwamariya C, Banerjee J, Bhowmick NA. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness. Oncogene 2010; 30: 167-177.
38. Kiskowski MA, Jackson 2nd RS, Banerjee J, Li X, Kang M, Iturregui JM et al. Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res 2011; 71: 3459-3470.
39. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL et al. Chromosomewide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 2005; 37: 853-862.
40. Oliveros JC 2007 http://www.bioinfogp.cnb.csic.es/tools/venny/index.html.